Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
54 results about "Thrombolytic treatment" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Thrombolytic therapy is a medical treatment used after many strokes or heart attacks, or other evidence of huge blood clots, to eliminate the clots. This type of therapy is drug-based and certain medicines are either administered intravenously (IV) or may be given through catheterization.
Cellular fibronectin as a diagnostic marker in stroke and methods of use thereof
InactiveUS20050130230A1Rapidly and accurately determinedMaximal sensitivityBiostatisticsDisease diagnosisStroke treatmentAssay
The present invention relates to methods for the diagnosis and evaluation of stroke and stroke sub-type. A variety of bio-markers are disclosed for assembling a panel for such diagnosis and evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects: the invention provides methods for early detection and differentiation of stroke subtypes, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for hemorrhagic transformation after thrombolyic therapy. Methods are disclosed that provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.
Owner:PREDICTION SCI
Cellular fibronectin as a diagnostic marker in cardiovascular disease and methods of use thereof
InactiveUS20080010024A1Reduce eliminateProlonged plasma half-lifeDisease diagnosisBiological testingCardiovascular InjuryCardiovascular Disorder
Thrombolytic therapy in the treatment of a cardiovascular event such as myocardial infarction (MI) carries with it a chance of suffering a hemorrhagic incident leading to severe disability and often death. Methods for the evaluation of proper therapy for a specific patient who has suffered a cardiovascular event employ a variety of bio-markers including cellular fibronectin (c-Fn) assembled as a panel for evaluation. Methods are disclosed for selecting markers and correlating their combined levels with a clinical outcome of interest. In various aspects the methods permit early detection of potential bleeding events, determination of the prognosis of a patient presenting cardiovascular damage, and identification of a patient at risk for hemorrhage when given thrombolytic therapy. The disclosed methods provide rapid, sensitive and specific assays to greatly reduce the risk of bleeding or the number of patients that can receive the most beneficial treatment for their cardiovascular event, and to reduce the human and economic costs associated with bleeding following such treatments.
Owner:PREDICTION SCI
Use of a mast cell activation or degranulation blocking agent in the manufacture of a medicament for the treatment of a patient subjected to thrombolyses
ActiveUS20060210551A1Reduction in serious hemorrhagicPrevented 39% of the brain edemaBiocidePeptide/protein ingredientsThrombusThrombolytic treatment
The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for preventing and treating cerebral complications caused by thrombolytic treatment. The invention also relates to treatment of patients suffering from cerebral complications associated with thrombolysis. Further, the invention provides thrombolytic compositions comprising a mast cell degranulation-blocking and / or mast cell activation-blocking agent present in a therapeutically effective amount to prevent or reduce any cerebral complications caused by the active thrombolytic component.
Owner:LINDSBERG PERTTU J +4
Shear controlled release for stenotic lesions and thrombolytic therapies
The invention provides compositions and methods for treating or imaging stenosis, stenotic lesions, occluded lumens, embolic phenomena or thrombotic disorders. The invention further provides compositions and methods for treating internal hemorrhage.
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Method and apparatus for creating penumbra and infarct images
InactiveUS20040138549A1Character and pattern recognitionComputerised tomographsRadiologyCerebral blood volume
A method and apparatus for evaluating acute stroke patients and for determining whether a stroke patient will benefit from the use of thrombolysis therapy includes obtaining measurements of the cerebral blood flow and cerebral blood volume of the brain of a stroke patient, determining ischemic areas of the brain where the ischemic areas comprise the measurements of cerebral blood flow which are less than a first value and creating a penumbra-infarct map of the ischemic areas of the brain using the measurements. The infarct area corresponds to the area of the brain where cerebral blood volume is less than a second value. The penumbra area corresponds to the area of the brain where cerebral blood volume is greater than this second dvalue. The method also includes determining a ratio of penumbra size to the total of penumbra size and infarct size. When the ratio is greater than a predetermined value, the stroke patient is a candidate for thrombolysis therapy.
Owner:UNIVERSITY OF LAUSANNE
Use of matrix metalloproteinase-10 (mmp-10) for thrombolytic treatments
InactiveUS20110091436A1Drop in maximum absorbency/turbidityAlter clot-formation ratePeptide/protein ingredientsPeptidasesThrombolytic treatmentThrombolytic Agent
The present invention relates to the use of matrix metalloproteinase MMP-10 in the preparation of a pharmaceutical composition useful for thrombolytic therapy, it also being possible for said composition to contain a plasminogen activator. Additionally, the present invention relates to said pharmaceutical composition for the treatment of thrombotic disorders.
Owner:PROYECTO DE BIOMEDICINA CIMA
Use of Prourokinase and Variants Thereof in Facilitated Percutaneous Coronary Intervention in Patients with Acute Myocardial Infarction
ActiveUS20110229454A1High selectivityPrevent hemorrhagic complicationPeptide/protein ingredientsEnzymesUrokinase Plasminogen ActivatorCardiac muscle
In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.
Owner:BOSTON PI CARDIO INC
Use of g-csf for the extension of the therapeutic time-window of thrombolytic stroke therapy
InactiveUS20120070403A1Effective treatmentImprove clinical outcomesNervous disorderHydrolasesSide effectMedicine
The present invention relates to the use of G-CSF and derivatives thereof for extending the therapeutic window of subsequent thrombolytic treatment of acute stroke, and thereby, allowing the diagnostic examinations which are necessary prior to the thrombolytic treatment in order to avoid hemorrhagic and other severe adverse side effects of the thrombolysis.
Owner:SYGNIS BIOSCIENCE GMBH & CO KG
Shear controlled release for stenotic lesions and thrombolytic therapies
Owner:PRESIDENT & FELLOWS OF HARVARD COLLEGE
Methods for pharmacologic treatment of stroke
ActiveUS20180280409A1Organic active ingredientsPharmaceutical delivery mechanismRisk strokeThrombolytic treatment
Described herein are methods for the treatment of a human subject who has had a stroke by administering to the subject a pharmaceutical composition including an antagonist of the P2X4 receptor. The antagonist of the P2X4 receptor can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.
Owner:UNITED STATES OF AMERICA +1
Novel patient subgroups for thrombolysis
A method for treating a stroke patient with thrombolysis, wherein prior to treatment the patient is diagnosed in particular for exhibiting cerebral tissue at risk, a cerebral artery occlusion, and / or an absolute “mismatch volume”.
Owner:H LUNDBECK AS
Process for the intracellular over-production of streptokinase using genetically engineered strain of E.coli
ActiveUS20050142653A1Increase productionImproved and economical processBiocideBacteriaBiotechnologyTrace element composition
An improved process for the production of streptokinase using a genetically engineered strain of Escherichia coli which overproduces streptokinase intracellularly and more particularly, the overall process disclosed herein, concerns with an improvement in the fermentative production of streptokinase using an optimized growth medium mainly comprised of simple salts and trace-elements; thus, in principal, the present process constitutes an improved and more economical means for the production of streptokinase which may be useful in thrombolytic therapy.
Owner:COUNCIL OF SCI & IND RES
Thrombus prevention and treatment catheter
InactiveCN105833414ATo achieve the purpose of thrombolytic therapyPrevent blood clotsMulti-lumen catheterMedical devicesAnticoagulantThrombus
The invention relates to the field of medical devices, in particular to a thrombus prevention and treatment catheter which comprises an indwelling catheter. The indwelling catheter comprises an inner catheter and an outer catheter; the outer catheter sleeves the inner catheter; spaces between the inner catheter and the outer catheter are filled with anticoagulants, and the anticoagulants can be outwardly permeated via the outer catheter. The thrombus prevention and treatment catheter has the advantages that hollow gaps are reserved between the inner catheter and the outer catheter of the indwelling catheter and are filled with the anticoagulants, the anticoagulants can be slowly released into the blood of patients via the outer catheter at certain speeds when the thrombus prevention and treatment catheter is used, and accordingly the purposes of preventing and treating thrombus can be achieved; the concentration of the filled anticoagulants can be regulated if the patients already suffer from the thrombus, or the release speeds of the anticoagulants can be regulated, so that the purpose of thrombolytic therapy can be achieved.
Owner:李炫
Ultrasonic thrombus removal accessory of implantable medical device
The invention discloses an ultrasonic thrombus removal accessory of an implantable medical device. The ultrasonic thrombus removal accessory of the implantable medical device comprises an ultrasonic transducer and an ultrasonic signal generation assembly, the ultrasonic transducer comprises a first ultrasonic transduction piece and a second ultrasonic transduction piece, and the first ultrasonic transduction piece and the second ultrasonic transduction piece are buckled together to form a mounting cavity, so that at least part of the implanted medical device is located in the mounting cavity, and the ultrasonic signal generation assembly is connected with the first ultrasonic transduction piece and the second ultrasonic transduction piece. The ultrasonic thrombus removal accessory of the implantable medical device can be installed on the outer surfaces of implantable devices such as an artificial heart and an artificial blood vessel in advance, thrombolysis treatment is conducted immediately when thrombus grows on the implantable devices, use is convenient, and the treatment effect is good.
Owner:BEIJING HEQINGHECHUANG MEDICAL TECH CO LTD
Targeted Thrombolysis for Treatment of Microvascular Thrombosis
PendingUS20210023187A1Easy to reorganizeEasy to integratePeptide/protein ingredientsAntibody mimetics/scaffoldsDiseaseZymogen
The present invention provides fusion proteins for targeted delivery of plasminogen activators to platelet-VWF complexes, or alternatively to the site where these are located, in a fibrin-independent manner. The fusion protein of the invention are for use in methods for the prevention or treatment of diseases or conditions associated with such platelet-VWF complexes, which may cause microvascular thrombosis in diseases such as e.g. thrombotic thrombocytopenic purpura. Preferred targeting agents for incorporation into the fusion proteins are e.g. nanobodies against VWF or platelets. Preferred plasminogen activators for use in the fusion proteins comprise the protease domains of uPA or tPA. The invention further pertains to nucleic acid molecule encoding the fusion proteins of the invention, e.g. a gene therapy vector, and to pharmaceutical compositions comprising the fusion proteins of the invention or such gene therapy vectors.
Owner:UMC UTRECHT HLDG BV
Method of using prourokinase in facilitated percutaneous coronary intervention in patients with acute myocardial infarction
ActiveUS9211317B2High selectivityAvoid complicationsPeptide/protein ingredientsHydrolasesUrokinase Plasminogen ActivatorIschemic myocardium
In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.
Owner:BOSTON PI CARDIO INC
Push sleeve applicable to intravenous thrombolysis catheter
InactiveCN104001254AAccurate and effective releaseReduce work intensityCatheterVeinThrombolytic drug
The invention provides a push sleeve applicable to an intravenous thrombolysis catheter. The push sleeve comprises a push sleeve tube body. The length of the push sleeve tube body is smaller than that of the intravenous thrombolysis catheter. The top end of the push sleeve tube body is provided with a marker line. The intravenous thrombolysis catheter is sleeved with the push sleeve tube body. After the intravenous thrombolysis catheter is implanted behind a blood clot, the push sleeve tube body is pushed, the length of a dosing part of the thrombolysis catheter is adjusted according to the marker line on the push sleeve tube body so that the length of the dosing part is identical to that of the blood clot, thrombolytic drug can be released more accurately and effectively, and the thrombolysis efficiency is improved; meanwhile, for a patient which accepts thrombolytic therapy once more, a thrombolysis catheter of a new specification does not need to be implanted again, and a doctor just needs to push the push sleeve tube body and determine a reasonable dosing interval; as a result, medical cost is lowered, the working intensity of medical workers is reduced, the problem of multiple specifications of the hrombolysis catheters is solved, and the push sleeve is reasonable, effective and convenient to operate.
Owner:TIANJIN JINYU RONGTONG BIOTECH CO LTD
Deep venous thrombolysis curative effect prediction method and system, storage medium and terminal
ActiveCN111145901AAchieving efficacy predictionReduce the burden onCharacter and pattern recognitionMedical automated diagnosisPrediction algorithmsVenous blood
The invention discloses a deep venous thrombolysis curative effect prediction method and system, a storage medium and a terminal. The method comprises the following steps: acquiring an MRI image of alower limb deep venous thrombosis patient; training the MRI image based on a semantic segmentation network to obtain a deep learning semantic segmentation model; extracting high-dimensional semantic features of lower limb deep vein thrombosis by adopting the deep learning semantic segmentation model, and performing feature screening on the high-dimensional semantic features by adopting a clustering algorithm; and performing lower limb deep venous thrombolysis curative effect prediction by adopting a thrombolysis curative effect prediction algorithm according to the screened semantic features to obtain a lower limb deep venous thrombolysis curative effect prediction result, and outputting the result. Based on the deep learning semantic segmentation network and the magnetic resonance image,the relation model between the semantic features and the thrombolysis curative effect of the thrombus is established, the thrombolysis curative effect of the thrombus of the patient is effectively predicted, the burden of doctors is relieved, and the diagnosis efficiency is improved.
Owner:SHENZHEN UNIV
5G intelligent driving emergency ambulance system special for cerebral apoplexy
PendingCN113053505AAvoid congestionShort driving routeMedical communicationMedical imagesEngineeringDiagnostic equipment
The invention discloses a 5G intelligent driving emergency ambulance system special for cerebral apoplexy. The system comprises a central emergency scheduling unit, an emergency ambulance emergency scheduling unit, a client emergency unit and a hospital terminal emergency scheduling unit. Compared with the prior art, the system has the following beneficial effects: 1, on one hand, road section congestion calculation can be carried out based on data of an urban transportation team, congested road sections are intelligently avoided, the driving route is as short as possible, and the optimal route selection for picking up and sending the patient is made, and automatic driving and driver driving can be realized; 2, corresponding diagnosis equipment for first aid of the stroke patient and thrombolysis necessary medicines and equipment are arranged in the emergency ambulance, so that thrombolysis treatment can be carried out on the stroke patient in the shortest time, and the disability probability and risk of the stroke patient are reduced; and 3, the mobile phone APP used by family members can timely check the driving condition of the emergency ambulance and the emergency condition of the patient for communication.
Owner:YANGEN UNIV
USE OF GINSENOSIDE Rb2 MONOMER IN THE MANUFACTURE OF MEDICAMENTS FOR THROMBOLYSIS
InactiveUS20100168406A1Resisting reperfusion injuryShorten bleeding timeOrganic active ingredientsSteroidsReperfusion injuryWhole body
The present invention discloses use of ginsenoside Rb2 in the manufacture of drugs. Said drugs not only can dissolve thrombi and protect against reperfusion injury, but also can improve microcirculation, help to repair the injured tissues and cells, improve local or even systemic physiological conditions. Additional advantages include reduced bleeding time when used in thrombolytic treatment. Said drugs may be used in a wide range of diseases related to microcirculatory disorders, such as chronic coronary heart disease, vasculitis, thromboembolic diseases, Raynaud's disease, microvascular diseases of fundus oculi and the like. According to the present invention, said drugs may be formulated into injections, tablets, granules or capsules. According to a basic embodiment of the present invention, the purity of ginsenoside monomer Rb2 may be around 80% and the rest components are essentially ginsenosides Rb1 and Rb3 in an amount of about 10%; the ginsenoside monomer Rb2 may also be in a purity of 90% or more.
Owner:CAI ZAIXI
Application of gastrodin in preparing drugs for treating cerebral hemorrhage
PendingCN110179808AProtect the brainOrganic active ingredientsPeptide/protein ingredientsDrugCentral nervous system
The present invention relates to the technical field of medicines, specifically relates to a use of gastrodin in preparing drugs for cerebral hemorrhage, particularly provides a use in preparing the drugs for reducing hemorrhagic transformation caused after a cerebral ischemia rt-PA thrombolytic therapy, and provides the use of the gastrodin in preparing the drugs for reducing the hemorrhagic transformation caused after the cerebral ischemia rt-PA thrombolytic therapy. The use suggests that a clinical early use of an gastrodin injection has a certain inhibitory effect for the existing hemorrhagic transformation caused by the use of the rt-PA thrombolytic therapy to treat ischemic stroke, can relatively extend time window of the rt-PA thrombolytic therapy, strives for more treatment time for patients with the clinical cerebral stroke, further reduces damages to central nervous system, enables prognosis to be better, reduces occurrence of sequelae and improves life quality of the patients.
Owner:KPC PHARM INC
Use of activated coagulation factor vii for treating thrombolytic therapy-induced major bleedings
Major bleedings induced by thrombolytic / fibrinolytic therapy, including intracranial haemorrhages, are treated by administering to a subject suffering from such bleedings an effective amount of activated coagulation factor VII (VIIa) or a functional derivative thereof.
Owner:BOEHRINGER INGELHEIM PHARM KG
Deep vein thrombosis thrombolytic effect prediction method and system, storage medium and terminal
ActiveCN111145901BAchieving efficacy predictionReduce the burden onCharacter and pattern recognitionMedical automated diagnosisPrediction algorithmsVenous blood
Owner:SHENZHEN UNIV
Methods for pharmacologic treatment of stroke
ActiveUS10695355B2Organic active ingredientsPharmaceutical delivery mechanismPharmaceutical drugThrombolytic treatment
Described herein are methods for the treatment of a human subject who has had a stroke by administering to the subject a pharmaceutical composition including an antagonist of the P2X4 receptor. The antagonist of the P2X4 receptor can be administered in the acute phase of stroke, optionally in combination with a thrombolytic therapeutic or a procedure on the subject involving a clot-removal device.
Owner:UNITED STATES OF AMERICA +1
Use of matrix metalloproteinase-10 (MMP-10) for thrombolytic treatments
Owner:PROYECTO DE BIOMEDICINA CIMA
Bionic nano-particles with antithrombotic function as well as preparation method and application of bionic nano-particles
ActiveCN114796488AProlonged Circulatory Half-LifeTo achieve the purpose of targeted enrichment drug therapyPeptide/protein ingredientsEnergy modified materialsThrombusIn vivo
The invention discloses bionic nano-particles with an antithrombotic function and a preparation method and application thereof, melanin nano-particles are extracted from ink sacs of cuttlefishes, platelet membranes are extracted from mouse blood, natural hirudin is wrapped in COF grafted outside the melanin nano-particles, then the platelet membranes are wrapped outside the natural hirudin for camouflage, and the bionic nano-particles with the antithrombotic function are obtained. Therefore, thrombus targeted thrombolysis treatment is realized. Natural hirudin is wrapped in COF outside melanin nanoparticles, the degradation effect of protease is reduced, the clearing speed of the natural hirudin in vivo is delayed, the bioavailability of the natural hirudin is improved, and in the long-term treatment process, the hirudin is slowly released and forms an irreversible compound with thrombin, so that recurrence of thrombus is inhibited. In addition, the platelet membrane is used for targeted positioning, body immune response does not exist, and the blood-pressure-sensitive hydrogel has good safety. And the bionic nanoparticles are combined with photothermal, so that the effect of rapid thrombolysis is achieved, and the biomimetic nanoparticles have good medical application prospects and practical value.
Owner:HUAZHONG AGRI UNIV
Intelligent device with laser thrombus crushing function
PendingCN113303904AAchieve cleanupSolve problems not suitable for thrombolytic therapyCatheterSurgical instrument detailsThrombusEngineering
The invention discloses an intelligent device with a laser thrombus crushing function, which comprises a tube sheath, a guide wire and a catheter, the guide wire and the catheter are sleeved at the front end of the tube sheath, the tube sheath is arranged in a tube sheath fixer, and a holmium laser instrument for emitting holmium laser and a vacuum tube device for vacuum extraction of thrombus are arranged outside the tube sheath fixer. An optical fiber and a delivery tube which are respectively connected with the holmium laser instrument and the vacuum tube device are arranged in the catheter sheath fixer, the optical fiber and the delivery tube extend in the catheter in the same direction and extend out, and a laser head used for smashing thrombus by laser is arranged at the extending end of the optical fiber. The intelligent device with the thrombus laser smashing function can conduct vacuum extraction after large thrombus is smashed through laser, the problem that a patient is not suitable for thrombolysis treatment is solved, the intelligent device is high in precision, small, exquisite, flexible and free of limitation, deliverability of a support is guaranteed, and the success rate of an operation is increased.
Owner:湖南早晨纳米机器人有限公司
Application of asarone in preparation of medicine for treating or preventing cerebral infarction hemorrhage transformation
PendingCN114010621AReduce volumeExtended respawn timeNervous disorderEther/acetal active ingredientsBrain edemaIonic Channels
The invention relates to the technical field of medicines, in particular to a novel application of alpha-asarone in preparation of a medicine for treating or preventing cerebral infarction hemorrhage transformation, and particularly relates to a novel application of alpha-asarone in preparation of a medicine for treating or preventing cerebral infarction hemorrhage transformation caused by thrombolytic therapy. The alpha-asarone can inhibit the current of the voltage-gated sodium ion channel, and can selectively act on the inactivated sodium ion channel and prolong the reactivation time of the sodium ion channel. Accordingly, it is found that alpha-asarone can significantly improve the neurological function score of a cerebral infarction hemorrhage transformation model rat, reduce the cerebral infarction volume, relieve encephaledema and improve blood-brain barrier permeability (reduce the content of Evans blue in brain tissue), and therefore nerve injury caused by cerebral infarction hemorrhage transformation is relieved. The clinical use of alpha-asarone is expected to be helpful for improving the prognosis of a cerebral apoplexy patient and prolonging the thrombolysis treatment time window of the cerebral apoplexy patient; the nerve injury of cerebral apoplexy patients is relieved, the death rate is reduced, and the life quality is improved.
Owner:SICHUAN UNIV
Use of G-CSF for the extension of the therapeutic time-window of thrombolytic stroke therapy
Owner:SYGNIS BIOSCI GMBH
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com